Head to Head Survey: Omnicell (OMCL) versus Fluidigm (FLDM)
Omnicell (NASDAQ: OMCL) and Fluidigm (NASDAQ:FLDM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
This is a summary of recent ratings and recommmendations for Omnicell and Fluidigm, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Omnicell presently has a consensus price target of $49.00, indicating a potential downside of 3.16%. Fluidigm has a consensus price target of $9.00, indicating a potential upside of 147.25%. Given Fluidigm’s stronger consensus rating and higher probable upside, analysts plainly believe Fluidigm is more favorable than Omnicell.
This table compares Omnicell and Fluidigm’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Omnicell has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Fluidigm has a beta of 3.45, suggesting that its share price is 245% more volatile than the S&P 500.
Institutional and Insider Ownership
96.4% of Omnicell shares are owned by institutional investors. Comparatively, 91.4% of Fluidigm shares are owned by institutional investors. 3.8% of Omnicell shares are owned by company insiders. Comparatively, 4.7% of Fluidigm shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Omnicell and Fluidigm’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Omnicell||$680.15 million||2.79||$42.68 million||($0.22)||-230.00|
|Fluidigm||$96.72 million||1.11||-$62.62 million||($2.46)||-1.48|
Omnicell has higher revenue and earnings than Fluidigm. Omnicell is trading at a lower price-to-earnings ratio than Fluidigm, indicating that it is currently the more affordable of the two stocks.
Omnicell beats Fluidigm on 9 of the 13 factors compared between the two stocks.
Omnicell, Inc. provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence. The Automation and Analytics segment is engaged in the design, manufacturing, selling and servicing of medication and supply dispensing systems, pharmacy inventory management systems and related software. The Medication Adherence segment includes the development, manufacturing and selling of consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services. Its products are used to manage medication administration outside of the hospital setting and include medication adherence products sold under the brand name MTS, Surgichem, SureMed and the Omnicell brand.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.